当前位置: 首页 > 详情页

VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1 alpha/VEGF and beta-catenin/Tcf-4 signaling

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Lab Neurooncol,Tianjin Neurol Inst, Tianjin, Peoples R China; [2]Minist Educ & Tianjin Municipal Govt, Key Lab Neurotrauma Variat & Regenerat, Tianjin, Peoples R China; [3]Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 2, Harbin, Peoples R China; [4]Capital Med Univ, Dept Neurosurg, Tiantan Hosp, Beijing, Peoples R China; [5]Tianjin Med Univ, Dept Neurol, Gen Hosp, Tianjin, Peoples R China; [6]Tianjin Neurol Inst, Lab Neurooncol, 154 Anshan Rd, Tianjin 300052, Peoples R China
出处:
ISSN:

关键词: glioma HIF-1 microRNA VHL -catenin

摘要:
Aberrant microRNA expression has been implicated in the development of human cancers. Here, we investigated the oncogenic significance and function of miR-23b in glioma. We identified that the expression of miR-23b was elevated in both glioma samples and glioma cells, indicated by real-time polymerase chain reaction analyses. Down-regulation of miR-23b triggered growth inhibition, induced apoptosis, and suppressed invasion of glioma in vitro. Luciferase assay and Western blot analysis revealed that VHL is a direct target of miR-23b. Restoring expression of VHL inhibited glioma proliferation and invasion. Mechanistic investigation revealed that miR-23b deletion decreased HIF-1/VEGF expression and suppressed -catenin/Tcf-4 transcription activity by targeting VHL. Furthermore, expression of VHL was inversely correlated with miR-23b in glioma samples and was predictive of patient survival in a retrospective analysis. Therefore, we demonstrated that downregulation of miR-23b suppressed tumor survival through targeting VHL, leading to the inhibition of -catenin/Tcf-4 and HIF-1/VEGF signaling pathways.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2011]版:
大类 | 2 区 医学
小类 | 2 区 临床神经病学 2 区 肿瘤学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 临床神经病学 1 区 肿瘤学
JCR分区:
出版当年[2010]版:
Q1 CLINICAL NEUROLOGY Q1 ONCOLOGY
最新[2023]版:
Q1 CLINICAL NEUROLOGY Q1 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2010版] 出版当年五年平均 出版前一年[2009版] 出版后一年[2011版]

第一作者:
第一作者机构: [3]Harbin Med Univ, Dept Neurosurg, Affiliated Hosp 2, Harbin, Peoples R China;
通讯作者:
通讯机构: [1]Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Lab Neurooncol,Tianjin Neurol Inst, Tianjin, Peoples R China; [2]Minist Educ & Tianjin Municipal Govt, Key Lab Neurotrauma Variat & Regenerat, Tianjin, Peoples R China; [6]Tianjin Neurol Inst, Lab Neurooncol, 154 Anshan Rd, Tianjin 300052, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16461 今日访问量:0 总访问量:871 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院